Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0000950170-25-050391
Filing Date
2025-04-03
Accepted
2025-04-03 16:10:44
Documents
21
Period of Report
2025-06-05

Document Format Files

Seq Description Document Type Size
1 PRE 14A crsp-20250403.htm   iXBRL PRE 14A 3010774
2 GRAPHIC img170269993_0.jpg GRAPHIC 87689
3 GRAPHIC img170269993_1.jpg GRAPHIC 66170
4 GRAPHIC img170269993_2.jpg GRAPHIC 640791
5 GRAPHIC img170269993_3.jpg GRAPHIC 544472
6 GRAPHIC img170269993_4.jpg GRAPHIC 573797
7 GRAPHIC img170269993_5.jpg GRAPHIC 1000094
8 GRAPHIC img170269993_6.jpg GRAPHIC 1419671
  Complete submission text file 0000950170-25-050391.txt   15441564

Data Files

Seq Description Document Type Size
9 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT crsp-20250403.xsd EX-101.SCH 7548
23 EXTRACTED XBRL INSTANCE DOCUMENT crsp-20250403_htm.xml XML 610374
Mailing Address BAARERSTRASSE 14 ZUG V8 CH-6300
Business Address BAARERSTRASSE 14 ZUG V8 CH-6300 6173154600
CRISPR Therapeutics AG (Filer) CIK: 0001674416 (see all company filings)

EIN.: 473173478 | State of Incorp.: V8 | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-37923 | Film No.: 25809520
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)